No offence, and with respect, your pessimism is starting to seem more like bitterness. How can you possibly have expected them to become cash flow positive in 2014? If management promised that without appropriately contextualising the statement with reference to the risks, then they could be behind bars!
CPPs are very likely to be in commercial use before PYC gets to market with a CPP-based pharma product. TAT based vaccines are in Phase 2 trials for HIV.
The CPP tech is great, but hasn't been where pharma companies have been focussing their late stage research. It is starting to come under increased focus as biologics (focussing on extracellular targets) become more popular, thereby making the intracellular drugable landscape, the next frontier. Pat yourself on the back for backing PYC early and seeing the potential.
For PYCs CPP tech to be commercialised, they need a pharma co to be able to deliver their proprietary drug cargoes into an intracellular target without causing any side effects. Genentech collaboration is the only warm iron in this respect. I'm not saying other collaborations may not come along, just pointing out that's the only live commercial collaborator they have.
As far as the proprietary myc-inhibitors go, the compounds work in-vitro, and work well, so it makes perfect sense for them to focus on cancer while keeping their options open to collaborate on CPP (or FPP) technology.
The animal trials are a HUGE step forward, but by no means the end of the pre-clinical stage. There is a lot of work to do before any compound(s) can go to Phase 1 IND trials. The animal trials are the first and significant step in this.
I expect the share price to trade in the 3-5c range if they get a successful result from animal trials as this would give me the early signal that the tox studies have a high likelihood of success. The tox, pharmacokinetics and drug-drug interaction studies should follow / or be concurrently pursued with the animal trials. Comprehensive tox studies cost money and take time. So it does not make sense to do them before the animal trials are finished. That is why it will take them till 2017 (whenever they said) to generate a final data pack.
At the time they generate the final data pack, they will need more money from a partner or shareholders to submit an IND study and go to Phase 1.
I don't mean to be patronising, and maybe all posters here knew all that, but a bit of perspective is necessary.
Let's keep the board and management honest, but also give them the time and space to prove themselves.
Let the good ship Phylogica set sail with full knowledge of the dangers that accompany a voyage of commercialisation.
I am betting that the animal model studies will be a success because they did one for the omomyc compound against triple negative breast cancer cells. Given all the in-vitro testing they have done of their proprietary myc inhibitor against omomyc, all the signs are very positive - better serum stability, kinetics, tox, etc
GLTAH
PYC Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)